FindTrial
Sign In

The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors

The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05360615
Enrollment
147
Registered
2022-05-04
Start date
2022-07-01
Completion date
2026-07-01
Last updated
2025-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Empagliflozin in Post AKI Stage 2-3

Keywords

Empagliflozin, AKI

Brief summary

Effects of Empagliflozin compared with placebo in post severe acute kidney injury survivors, evaluated by MAKE365.

Interventions

DRUGEmpagliflozin 10 MG

SGLT2 inhibitors

DRUGPlacebo

Placebo

Sponsors

Chulalongkorn University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* post AKI stage 2-3 * CrCl \> 20

Exclusion criteria

* pregnancy * post kidney transplant * previous use of SGLT2 Inhibitors * history of ketoacidosis

Design outcomes

Primary

MeasureTime frameDescription
MAKE3651 yearMajor adverse kidney events (number of participants with death, renal replacement therapy, New CKD, CKD progression)

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026